These limitations notwithstanding, our findings support considerations to use aminobisphosphonates like zoledronate – or related γδ T‐cell‐stimulating treatments such as HMB‐PP analogues or anti‐BTN3 agonistic antibodies – as novel immunotherapies in sepsis patients. This evidence concerns the gene BTNL9 and Sepsis.